Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chien‐shan Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4885-6759; OpenAlex author ID A5065904970. Sources: OpenAlex.

Their work

Papers
33 (first author 13, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 4 papers · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 3 papers · 2023: 5 papers · 2024: 7 papers · 2025: 2 papers

Papers 33

  1. Strand-specific functions of miR-301a-3p and -5p drive opposing roles in pancreatic cancer via ferroptosis and pyroptosis. Co-author DOI 10.1007/s10565-025-10096-6↗
  2. Identification of Syndrome Types in Patients With Pancreatic Cancer From Free Text in Electronic Medical Records: Model Development and Validation. Co-author DOI 10.2196/70602↗
  3. Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related genes: an in silico analysis with in vitro a… Co-author DOI 10.1007/s00280-024-04663-7↗
  4. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression. Co-author DOI 10.1016/j.prp.2023.155046↗
  5. Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pa… First author DOI 10.1088/1361-6528/ad312a↗
  6. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. Co-author DOI 10.1177/2515690x241291381↗
  7. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… First author DOI 10.1186/s12885-024-12695-8↗
  8. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma. Co-author DOI 10.31083/j.fbl2903119↗
  9. Cynanchum paniculatum (Bunge) Kitag. ex H.Hara inhibits pancreatic cancer progression by inducing caspase-dependent apoptosis and suppressing TGF-β-mediated ep… Co-author DOI 10.3389/fphar.2024.1284371↗
  10. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34334↗
  11. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Co-author DOI 10.1016/j.apsb.2023.01.020↗
  12. Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic fac… Co-author DOI 10.1080/02656736.2023.2278417↗
  13. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation. Co-author DOI 10.1186/s10020-023-00648-z↗
  14. Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validation. First author DOI 10.1186/s12885-023-10597-9↗
  15. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. First author DOI 10.1016/j.jep.2021.114691↗
  16. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. Co-author DOI 10.1016/j.jep.2022.115516↗
  17. Fibroblast activation protein-based theranostics in pancreatic cancer. Co-author DOI 10.3389/fonc.2022.969731↗
  18. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Co-author DOI 10.1002/ctm2.467↗
  19. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. Co-author DOI 10.1186/s12885-021-08158-z↗
  20. HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer. Co-author DOI 10.1186/s12920-021-01043-5↗
  21. Overexpression of Interferon-Inducible Protein 16 Promotes Progression of Human Pancreatic Adenocarcinoma Through Interleukin-1β-Induced Tumor-Associated Macro… First author DOI 10.3389/fcell.2021.640786↗
  22. Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling. Co-author DOI 10.1186/s13578-020-00457-5↗
  23. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. First author DOI 10.18632/aging.102638↗
  24. Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through the Inhibition of TGF-β1/Smad Signaling and Epithelial-Mesenchymal-Transition. Co-author DOI 10.2147/cmar.s224416↗
  25. Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. First author DOI 10.3389/fonc.2020.520330↗
  26. Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Co-author DOI 10.1016/j.bbrc.2019.02.092↗
  27. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2019/1356264↗
  28. Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibiti… First author DOI 10.18632/aging.101940↗
  29. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. First author DOI 10.1016/j.bbrc.2018.04.137↗
  30. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. First author DOI 10.1155/2018/7343090↗
  31. Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. First author DOI 10.2147/cmar.s167103↗
  32. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. First author DOI 10.3390/ijms19061768↗
  33. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. First author PMID 27448780↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Chen · 18 shared papers, 2018–2025 · strength 2.78
  2. Lianyu Chen · 14 shared papers, 2018–2025 · strength 2.03
  3. Juying Jiao · 8 shared papers, 2021–2024 · strength 1.66
  4. Peiwen Yang · 6 shared papers, 2022–2024 · strength 1.35
  5. Linjie Ruan · 5 shared papers, 2023–2025 · strength 1.20
  6. Zhiqiang Meng · 9 shared papers, 2018–2023 · strength 1.16
  7. Shu Dong Ma · 5 shared papers, 2022–2024 · strength 1.16
  8. Panling Xu · 4 shared papers, 2022–2024 · strength 0.85
  9. Zhangqi Cao · 4 shared papers, 2021–2024 · strength 0.83
  10. Fengjiao Wang · 4 shared papers, 2021–2024 · strength 0.78
  11. Yanhua Jing · 3 shared papers, 2021–2024 · strength 0.59
  12. Yuhang Chen · 2 shared papers, 2024–2025 · strength 0.56
  13. He Ba · 2 shared papers, 2024–2025 · strength 0.54
  14. Hao Chen · 4 shared papers, 2018–2024 · strength 0.48
  15. Jingxian Chen · 3 shared papers, 2020–2024 · strength 0.48
  16. Lan Zheng · 3 shared papers, 2020–2024 · strength 0.48
  17. Ailing Zhong · 3 shared papers, 2019–2023 · strength 0.47
  18. Ke Zhang · 2 shared papers, 2024 · strength 0.43
  19. Ping Li · 2 shared papers, 2022–2023 · strength 0.42
  20. Jiangang Zhao · 2 shared papers, 2020–2025 · strength 0.42
  21. Changjing Huang · 2 shared papers, 2023–2024 · strength 0.40
  22. Chao Qu · 4 shared papers, 2018–2021 · strength 0.38
  23. Peng Wang · 3 shared papers, 2018–2023 · strength 0.38
  24. Yibin Feng · 2 shared papers, 2021–2023 · strength 0.34
  25. Ning Wang · 2 shared papers, 2021–2023 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.